01-18-2019 08:22 AM CET - Business, Economy, Finances, Banking & Insurance

Dercum’s Disease Market 2018 Global Leaders Overview: Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis and others

Press release from: Market Research Future
Dercum’s Disease Market
Dercum’s Disease Market

Market Scenario

The global Dercum’s Disease treatment market is expected to register a significant growth during the forecast period (2018–2023).

Legg-calve-perthes is a disease which occurs when the blood supply to the femoral head (upper end of the thigh bone) which fits in the hip socket temporarily stops to flow. As an outcome, the femoral head is no longer round and does not move smoothly in the hip socket, resulting in hip pain and constrained leg movements.

Dercum’s Disease (LCPD) generally occurs in children of age 4 to 10 years. Individuals suffering from the disease go on developing a painful joint disorder called as osteoarthritis in the hips at an early age. Individuals suffering from the Dercum’s Disease are often short compared to healthy individuals due to bone anomalies.

Key players

Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis,Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, Amgen, Valeant Pharmaceuticals, Syneron Medical, St. Jude Medical Inc. and Alimed, Inc. are some players in the global dercum’s disease market.

Get Sample Copy @ www.marketresearchfuture.com/sample_request/6350


The global dercum’s disease market has been segmented into treatment, distribution channel, and end-user.

The market, on the basis of treatment, has been segmented into surgery, medication, liposuction, electrotherapy, acupuncture, and others. The medication segment has been further segmented into diuretics, non-steroidal anti-inflammatory drugs, corticosteroids, and others.

The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.

The market, by end-user, has been segmented into hospital & clinics, ambulatory surgical centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dercum’s disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European dercum’s disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The dercum’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The dercum’s disease market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global dercum’s disease market owing to a well-established healthcare sector, rising prevalence of rare diseases, and growing healthcare expenditure. According to the data published in the National Center for Biotechnology Information (NCBI) in 2017, about 25 to 30 million American population live with a rare disease. Additionally, favorable reimbursement scenario and a relatively large number of research and development (R&D) activities contribute to the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in the US, the total national health expenditure was USD 3.2 trillion in the year 2015.

Europe is expected to hold the second largest position in the global dercum’s disease market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.

The dercum’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing disposable income, continuously developing economies, and increasing government funding for the healthcare sector. Additionally, regional expansions by market players in the region are considered to be contributing to the market growth.

The Middle East & Africa has the least market share in the global market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ www.marketresearchfuture.com/reports/dercums-disease-mark...


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.
News-ID: 1511075 • Views: 138
More releasesMore releases

You can edit or delete your press release here: